Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, beganshipping its Molecular Coincidence Detection high-energy imagingupgrade this year, and reported that it had received 27 ordersfor MCD upgrades through the end of its fiscal year in
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, beganshipping its Molecular Coincidence Detection high-energy imagingupgrade this year, and reported that it had received 27 ordersfor MCD upgrades through the end of its fiscal year in September.ADAC plans to show improvements in reconstruction algorithms forMCD at its RSNA booth, according to Jeff Nelson, vice presidentof marketing.
Also look for ADAC to present final results of its multicenterclinical trial for Vantage, an attenuation-correction feature.The results indicate that Vantage can help reduce false positivesin nuclear cardiology studies, Nelson said. ADAC has developeda second-generation version of Vantage that incorporates scattercorrection and gated SPECT.
Vertex Plus is the third generation of ADAC's variable-angledual-head gamma camera, and features improvements to the system'sergonomics and patient handling, according to Nelson.
The most interesting news at ADAC's booth, however, isn't relatedto a new product, but rather an acquisition with intriguing ramifications:sources indicate the vendor will annouce the purchase of managedservice organization Medical Transition Strategies of Atlanta,the parent of Georgia Radiology Network.
ADAC is expected to form a new business unit to encompass itswork in developing physician networks that can contract with payorslike managed-care organizations. ADAC could use Georgia RadiologyNetwork as a model in setting up radiology networks in other states.The company declined to comment officially on the acquisitionprior to the RSNA show.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.